Treatment of basal cell carcinoma with intralesional interferon alfa-2b: an open-label clinical trial.

IF 2.9 3区医学 Q2 ONCOLOGY Expert Review of Anticancer Therapy Pub Date : 2023-07-01 Epub Date: 2023-06-05 DOI:10.1080/14737140.2023.2219449

Masoud Maleki, Pouran Layegh, Bita Kiafar, Mehrdad Teimoorian, Emadodin Darchini-Maragheh, Mahdi Razmara

{"title":"Treatment of basal cell carcinoma with intralesional interferon alfa-2b: an open-label clinical trial.","authors":"Masoud Maleki, Pouran Layegh, Bita Kiafar, Mehrdad Teimoorian, Emadodin Darchini-Maragheh, Mahdi Razmara","doi":"10.1080/14737140.2023.2219449","DOIUrl":null,"url":null,"abstract":"Introduction: Basal cell carcinoma (BCC) is the most common cutaneous cancer. We report the efficacy and aesthetic outcome of intralesional IFN-α 2b injection for the treatment of BCC and compare with the surgical method.Materials and methods: Intralesional IFN-α 2b was injected in 58 BCC lesions from 20 patients three times a week for three weeks. Control group was retrospectively selected among patients who underwent surgical method (standard surgical excision) for BCC including 58 lesions from 24 patients. All patients were followed up for one year in terms of recurrence and cosmetic outcome.Results: Two patients (four lesions) failed to complete the treatment period. After three weeks, 40 (68.96%) lesions were completely cured. Nine (15.51%) lesions achieved complete healing in less than 9 sessions. Five (8.62%) lesions were completely cured by an extra week of injection. In aggregate, complete healing was observed in 54 (93.10%) lesions. In the surgery group, complete lesion elimination was detected in 52 (89.65%) lesions (p = 0.40). After one year, cosmetic outcome was significantly more favorable in the study group compared to the surgery group (p = 0.003). Recurrence was not detected in any of the groups after one year follow-up.Conclusion: Intralesional IFN-α 2b injection is an appropriate treatment choice for BCC.Clinical trial registry: We used Iranian registery of Clinical trials; The IRCT code is: 2017093017756N30.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":"23 7","pages":"753-760"},"PeriodicalIF":2.9000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Anticancer Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737140.2023.2219449","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/6/5 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Basal cell carcinoma (BCC) is the most common cutaneous cancer. We report the efficacy and aesthetic outcome of intralesional IFN-α 2b injection for the treatment of BCC and compare with the surgical method.

Materials and methods: Intralesional IFN-α 2b was injected in 58 BCC lesions from 20 patients three times a week for three weeks. Control group was retrospectively selected among patients who underwent surgical method (standard surgical excision) for BCC including 58 lesions from 24 patients. All patients were followed up for one year in terms of recurrence and cosmetic outcome.

Results: Two patients (four lesions) failed to complete the treatment period. After three weeks, 40 (68.96%) lesions were completely cured. Nine (15.51%) lesions achieved complete healing in less than 9 sessions. Five (8.62%) lesions were completely cured by an extra week of injection. In aggregate, complete healing was observed in 54 (93.10%) lesions. In the surgery group, complete lesion elimination was detected in 52 (89.65%) lesions (p = 0.40). After one year, cosmetic outcome was significantly more favorable in the study group compared to the surgery group (p = 0.003). Recurrence was not detected in any of the groups after one year follow-up.

Conclusion: Intralesional IFN-α 2b injection is an appropriate treatment choice for BCC.

Clinical trial registry: We used Iranian registery of Clinical trials; The IRCT code is: 2017093017756N30.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

用局部干扰素 alfa-2b 治疗基底细胞癌：一项开放标签临床试验。

简介：基底细胞癌（BCC）是最常见的皮肤癌：基底细胞癌（BCC）是最常见的皮肤癌。我们报告了局部注射 IFN-α 2b 治疗 BCC 的疗效和美学效果，并与手术方法进行了比较：对 20 名患者的 58 个 BCC 病灶进行了 IFN-α 2b 局内注射，每周三次，持续三周。对照组是从接受手术方法（标准手术切除）治疗 BCC 的患者中回顾性选出的，包括 24 名患者的 58 个病灶。所有患者均接受了为期一年的复发和美容效果随访：结果：两名患者（4 个病灶）未能完成治疗。三周后，40 个病灶（68.96%）完全治愈。9个病灶（15.51%）在不到9次治疗后完全愈合。5个（8.62%）病灶在多注射一周后完全愈合。总共有 54 个（93.10%）病灶完全愈合。在手术组中，52 个（89.65%）病灶完全消除（P = 0.40）。一年后，研究组的美容效果明显优于手术组（p = 0.003）。随访一年后，各组均未发现复发：临床试验登记：我们使用了伊朗临床试验注册表；IRCT 代码为：2017093017756N30。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Expert Review of Anticancer Therapy 医学-肿瘤学

CiteScore

5.10

自引率

3.00%

发文量

100

审稿时长

4-8 weeks

期刊介绍： Expert Review of Anticancer Therapy (ISSN 1473-7140) provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches. Coverage includes tumor management, novel medicines, anticancer agents and chemotherapy, biological therapy, cancer vaccines, therapeutic indications, biomarkers and diagnostics, and treatment guidelines. All articles are subject to rigorous peer-review, and the journal makes an essential contribution to decision-making in cancer care. Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections: Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.